Author： Shusterman Neil
Publisher： Informa Healthcare
ISSN： 1474-0338
Source： Expert Opinion on Drug Safety, Vol.1, Iss.2, 2002-07, pp. : 137-152
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Access to resources
Recommend
Angiotensin II receptor antagonists -
Expert Opinion on Investigational Drugs, Vol. 6, Iss. 5, 1997-05 ,pp. :
A Risk-Benefit Assessment of Abciximab in Angioplasty
By Kleiman N.S.
Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. :
A Risk-Benefit Assessment of Amifostine in Cytoprotection
By Mabro M.
Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. :
A Risk-Benefit Assessment of Antileukotrienes in Asthma
By Smith L.J.
Drug Safety, Vol. 19, Iss. 3, 1998-09 ,pp. :